

Constantin A Dasanu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7384536/publications.pdf>

Version: 2024-02-01

58
papers

511
citations

840728

11
h-index

713444

21
g-index

58
all docs

58
docs citations

58
times ranked

763
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib. <i>Journal of Clinical Oncology</i> , 2008, 26, 4047-4048.	1.6	51
2	Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 231-234.	0.9	48
3	Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. <i>BBA Clinical</i> , 2016, 6, 12-18.	4.1	46
4	Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2052-2055.	0.9	31
5	Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1481-1494.	1.8	29
6	Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1520-1522.	0.9	26
7	Complete heart block secondary to bortezomib use in multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 282-284.	0.9	24
8	Late-onset robust curly hair growth in a patient with BRAF-mutated metastatic melanoma responding to dabrafenib. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 309-312.	0.9	24
9	ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival. <i>Current Medical Research and Opinion</i> , 2018, 34, 757-763.	1.9	21
10	Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 966-968.	0.9	21
11	Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 638-640.	0.9	18
12	Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 99-104.	3.1	14
13	Autoimmune disorders in patients with hairy cell leukemia: are they more common than previously thought?. <i>Current Medical Research and Opinion</i> , 2015, 31, 17-23.	1.9	12
14	Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 638-647.	0.9	12
15	Autoimmune disorders in patients with T-cell lymphoma: a comprehensive review. <i>Current Medical Research and Opinion</i> , 2015, 31, 1861-1870.	1.9	8
16	Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1531-1533.	0.9	8
17	Primary squamous cell carcinoma of the thyroid with complete response to radical radiotherapy and concurrent cisplatin-based chemotherapy. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016217143.	0.5	7
18	Polymyalgia rheumatica due to pembrolizumab therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1282-1284.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Immune alterations in untreated and treated myelodysplastic syndrome. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 351-361.	2.4	6
20	Severe phototoxic reaction secondary to subcutaneous 5-azacitidine. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 473-475.	0.9	6
21	Angioedema late in the course of adjuvant nivolumab therapy for melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1019-1021.	0.9	6
22	Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522097679.	0.9	6
23	Advanced papillary thyroid carcinoma responding to nivolumab. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 453-456.	0.9	6
24	Bluish-gray fingernail discoloration due to the use of nivolumab. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 457-459.	0.9	6
25	Sustained erythrocytosis due to the use of Lenvatinib. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110391.	0.9	6
26	Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1003-1005.	0.9	5
27	Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 990-992.	0.9	5
28	Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217000.	0.5	5
29	Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 226-228.	0.9	4
30	Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 214-216.	0.9	4
31	Severe terminal ileitis induced by single-agent nivolumab administered every four weeks. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1516-1519.	0.9	4
32	Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 229-231.	0.9	3
33	Clinico-epidemiologic characteristics and patterns of care in Kaposi's sarcoma: Data from a single-institution series. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1719-1721.	0.9	3
34	Management and clinical outcomes in uterine malignant mixed Müllerian tumor: Lessons from a single-institution series. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 688-691.	0.9	3
35	Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1775-1778.	0.9	3
36	Cystic acne due to imatinib therapy for chronic myelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 972-974.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110297.	0.9	2
38	Evolving therapeutic strategies for advanced hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-12.	1.8	2
39	Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 722-724.	0.9	2
40	Necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma, reversed by pegylated liposomal doxorubicin. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1003-1008.	0.9	2
41	A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210877.	0.9	2
42	Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 549-551.	0.9	1
43	Adenocarcinoma of the appendix occurring in a patient treated with paclitaxel for locally advanced esophageal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 150-152.	0.9	1
44	Impact of therapeutic modalities on disease-specific survival in older adults with glioblastoma: A single-institution retrospective cohort study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1999-2003.	0.9	1
45	Severe left atrial enlargement due to carfilzomib use in multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2045-2048.	0.9	1
46	Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2016-2018.	0.9	1
47	Clinico-epidemiologic characteristics and patterns of care in Kaposi Sarcoma: Data from a single-institution series.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13585-e13585.	1.6	1
48	Clinico-epidemiologic characteristics and patterns of care in glioblastoma multiforme: Data from a single-institution series.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14069-e14069.	1.6	1
49	Age-related clinicopathologic features and survival in papillary serous uterine cancer patients older and younger than 70: An exploratory analysis of a series of consecutive patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18104-e18104.	1.6	1
50	Development of Monoclonal B-cell Lymphocytosis Shortly After Treatment with Nivolumab and Subsequent Progression to Chronic Lymphocytic Leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210740.	0.9	1
51	Cecal volvulus associated with carfilzomib use for AL amyloidosis. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1230-1233.	0.9	1
52	Merkel cell carcinoma: long-term follow-up of a single institution series and clinical outcomes by immunological status. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	1
53	Reply To the Editor. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 575-576.	0.9	0
54	Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1025-1028.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Multidirectional pattern of hair growth with carflizomib use for multiple myeloma. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522096454.	0.9	0
56	5-azacitidine reversing â€œspentâ€•phase polycythemia vera back to proliferative phase and need for phlebotomy. Journal of Oncology Pharmacy Practice, 2020, 26, 1285-1288.	0.9	0
57	Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?. Journal of Oncology Pharmacy Practice, 2021, 27, 205-206.	0.9	0
58	Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors?. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522110157.	0.9	0